Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor ...
Investor's Business Daily on MSN
The Wild Ride That Sent IBD Stock Of The Day Insulet Into An Early Breakout
Insulet is Thursday's IBD Stock Of The Day. After a wild post-earnings reaction, Insulet stock is in a consolidation with an ...
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered DexCom losses, you mayCLICK HERE or copy and paste the following link into your browser: ...
Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring ...
Sophie Clarke speaks to Ellen Watson and Beth McDaniel, better known as the Diabetic Duo, about living with type 1 diabetes and inspiring others online ...
StockStory.org on MSN
Winners And Losers Of Q3: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks
Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including DexCom ...
DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.
Company: DexCom is a medical device company primarily focused on the design, development, and commercialization of continuous glucose monitoring ("CGM") systems for the management of diabetes and ...
Lead Plaintiff Deadline is December 26, 2025 NEW YORK, Nov. 11, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that ...
Since last year, DexCom ( DXCM +5.54%) has faced a series of issues that have sunk its stock price. The medical device ...
The musician talks about the Jonas Brothers' tour, their first holiday movie, his tenth anniversary of Beyond Type 1, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback